-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, September 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
IDWeek 2026: Pre-Conference Coverage
The IDWeek Global Annual Meeting 2026 will take place in Washington, DC, US from October 21–24. Use this report to: Prepare for IDWeek 2026 by reviewing high-impact, potentially practice-changing abstracts, including those of breakthrough therapies that could redefine treatment paradigms. This report also spotlights emerging therapies that may not yet be widely recognized but represent significant clinical and commercial opportunities.
-
Sector Analysis
Gonorrhea: Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Gonorrhea Therapeutics. - In 2025, there were more than 2.75 million diagnosed incident cases of GC in the 16 countries covered in GlobalData’s epidemiology forecast. - The GC market remains largely generic, with approved treatments spanning several antibiotic classes including penicillin antibiotics, sulfonamides, fluoroquinolones, tetracyclines, azalide derivatives, aminopenicillins, and macrolides. - Treatment has evolved from fluoroquinolone monotherapy to ceftriaxone–azithromycin dual therapy and, since 2020, ceftriaxone 500...
-
Sector Analysis
Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035
Ulcerative colitis (UC) is the most common type of inflammatory bowel disease (IBD). Worldwide, the highest number of incident and prevalent cases of UC are reported in Europe and North America (Heydari et al., 2025). UC presents as a chronic disease in which abnormal reactions of the immune system cause inflammation and ulcers on the inner lining of the large intestine, especially the colon and rectum, causing complete damage to the lining (National Institute of Diabetes and Digestive and Kidney...
-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035. - In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035. - There will be an increase in therapies with longer duration of action, such...
-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q3 2026
This report analyzes the venture capital (VC) investment activity in Q3 2026 in the Pharma sector.
-
Track & Monitor
Merger and Acquisition (M&A) Trends in Pharma - Q3 2026
This report analyzes the merger and acquisition (M&A) activity in Q3 2026 in the Pharma sector.
-
Sector Analysis
Alzheimer’s Disease in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM.he US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2...
-
Sector Analysis
Parkinson's Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimated that the PD market was $3.3 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.2 billion, increasing at a compound annual growth rate (CAGR) of 7.9%. The major drivers of growth in the PD market will be the launch of several pipeline products including novel...
-
Sector Analysis
Acute-on-Chronic Liver Failure: Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Acute-on-Chronic Liver Failure Therapeutics. In 2025, there were 72,095 diagnosed incident cases of ACLF in the 16 countries covered in GlobalData’s epidemiology forecast. Acute-on-Chronic Liver Failure (ACLF) management is largely supportive and focused on complications because there is no approved therapy specifically for ACLF. Standard interventions include antimicrobials (e.g., piperacillin–tazobactam, ceftriaxone/cefotaxime, meropenem, vancomycin/linezolid), vasopressors and fluids (norepinephrine ± vasopressin), albumin/crystalloids, HBV antivirals (tenofovir or entecavir), and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.